Vitaspring Biomedical Co., Ltd. income statement VSBC

Annual Quarterly

In fiscal 2026, which ended Jan 31, 2026, Vitaspring Biomedical Co., Ltd. reported revenue of $0. It recorded a net loss of $415,368. Diluted earnings per share were $0.00. Over the twelve months ended Jul 31, 2026, revenue was $0 and the net loss was $455,643. Across the 5 fiscal years shown, revenue grew from $16,230 in fiscal 2018 to $5.6 million in fiscal 2021, about 331.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2027 Jul 31, 2026	FY 2026 Jan 31, 2026	FY 2025 Jan 31, 2025	FY 2024 Jan 31, 2024	FY 2023 Jan 31, 2023	FY 2021 Jan 31, 2022	FY 2021 Jan 31, 2021	FY 2020 Jan 31, 2020	FY 2019 Jan 31, 2019	FY 2018 Jan 31, 2018
Revenue	0	0	0	0	0	6 +36975.3%	0 +1539.4%	0 -11.9%	0 +5.9%	0
Cost of revenue	—	0	—	0 -100.0%	3	4 +26268.2%	0 +911.5%	0	—	0
Gross profit	—	0	—	0 +100.0%	-3	2 +121905.9%	0 +6519.5%	0 -87.6%	0 +21.0%	0
Selling, general and administrative	0 +48.3%	0 -43.3%	1 -39.2%	1 +32.4%	1	1 +4344.0%	1 +2437.9%	0 -41.3%	0 +103.9%	0
Operating expenses	—	0	—	1 +32.4%	1	1	—	—	0	—
Operating income	-0 -10.2%	-0 +43.3%	-1 +39.2%	-1 +73.2%	-4	1	0	—	-0	—
Pretax income	-0 -8.8%	-0 +43.3%	-1 +39.2%	-1 +73.2%	-4	1 +16183.6%	-0 -6248.0%	0	—	—
Income tax	0 -94.3%	0 -68.5%	0	0 +100.0%	-0	0	0	0	—	—
Net income	-0 +14.2%	-0 +46.4%	-1 +30.7%	-1 +73.1%	-4	1 +13045.8%	0 +6048.0%	0 +130.9%	-0 -251.4%	-0
Diluted EPS	-0.00 +14.2%	0.00	0.00 +100.0%	-0.01 +50.0%	-0.02	—	—	—	—	—
Weighted average shares, basic	—	—	—	—	—	206	—	—	—	—
Weighted average shares, diluted	207 +0.0%	207 +0.0%	207 +0.0%	207 +0.2%	207	—	91 +735.5%	11 +11.0%	10 +328.3%	2
Other measures
Depreciation and amortization	—	0	—	0 +0.0%	0	0 -100.0%	0 -100.0%	0 +0.0%	0 +20.0%	0
EBITDA	—	-0	—	-1 +73.5%	-4	1	0	—	-0	—
Margins
Gross margin	—	—	—	—	—	36.84%	45.21%	11.20%	79.85%	69.88%
Operating margin	—	—	—	—	—	20.07%	171.39%	—	-130.36%	—
Pretax margin	—	—	—	—	—	20.07%	-171.39%	45.70%	—	—
Profit margin	—	—	—	—	—	16.20%	171.39%	45.70%	-130.36%	-39.27%
EBITDA margin	—	—	—	—	—	20.07%	171.39%	—	-127.74%	—
Effective tax rate	—	—	—	—	—	19.27%	—	0.00%	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Services-Commercial Physical & Biological Research (SIC 8731)
Listed as: VSBC (OTC)
Fiscal year ends: January 31
Incorporated in: NV
Headquarters: Riverside, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1697884
Former names: Shemn Corp. (until Apr 27, 2020)

Other Services-Commercial Physical & Biological Research companies

Iqvia Holdings Inc. IQV
Incyte Corp INCY
Medpace Holdings, Inc. MEDP
Charles River Laboratories International, Inc. CRL
Icon PLC ICLR
Absci Corp ABSI
OmniAb, Inc. OABI
NRC Health NRC

All 17 Services-Commercial Physical & Biological Research companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.